Official ILC 2022 press programme
OFFICIAL PRESS CONFERENCE ABSTRACTS: ALL ORAL AND POSTER ABSTRACTS PRESENTED IN AN OFFICIAL PRESS CONFERENCE ARE EMBARGOED UNTIL THE TIME AND DATE OF THE START OF THE PRESS CONFERENCE IN WHICH THEY ARE DELIVERED.
ILC 2022 Press Conferences are only accessible live to registered media. Press conferences will take place at London ExCeL in Capital Suite 5, and will be accessible through the online ILC platform.
To register your attendance of the press conferences, please proceed with the following steps:
- Go to the online ILC platform
- To login, enter your email address that you used to register for ILC. If this is the first time that you're accessing the online ILC platform, you'll be asked to create a password.
- Once you have entered the online ILC platform, click on "PRESS PROGRAMME",
- Select the Press Conference you wish to attend (filtered by date)
- Click on "Add to my schedule" - you are now registered to the press conference.
Please note: Press programme subject to changes
| TIME (BST) | THEME / TOPIC | TIME OF ABSTRACT | SPEAKERS | ||||||||
| PRESENTATIONS | |||||||||||
| Thursday June 23 | ILC 2022 Official Opening Press Conference 1: Hepatitis | Chair: Thomas Berg, Secretary General, EASL | |||||||||
| 11:30-12:15 BST | |||||||||||
| Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary endpoint results from a phase 3 randomized, multicenter, parallel design study (GS006) | Thursday 23 June 13:30 - 15:00 BST |
Heiner Wedemeyer, Clinic Director, Prof. Dr, Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany | |||||||||
| Efficacy and safety of givosiran in patients with acute hepatic porphyria: 36-month results of the phase 3 ENVISION randomised clinical trial (OS075) | Friday 24 June 10:00 - 11:30 BST |
Manish Thapar, Associate Professor, Thomas Jefferson University, Philadelphia, United States | |||||||||
| Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study (GS010) | Friday 24 June 13:40 - 15:40 BST |
Kosh Agarwal, Consultant Hepatologist and Transplant Physician, Institute of Liver Studies, King’s College Hospital, United Kingdom | |||||||||
| Multicenter prospective study for the use of shortened pre-emptive therapy with Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in hepatitis C (HCV) seronegative non-liver solid organ transplant recipients of HCV viremic grafts (OS002) | Thursday 23 June 16:00 - 17:30 BST |
Bashar Aqel, M.D. Mayo Clinic, Gastroenterology, Hepatology and Liver Transplant, Phoenix, United States | |||||||||
| High Intensity Test and Treat (HITT): an overview of the initiative as part of the hepatitis C elimination programme in England (OS053) | Friday 24 June 10:00 - 11:30 BST |
Beatrice Emmanouil, NHS England & NHS improvement, United Kingdom | |||||||||
| Thursday 23 June 12:20 - 13:00 BST |
Media Briefing (in-person only) Update on cases of acute hepatitis in children. |
Thursday 23 June 12:20 - 13:00 BST |
Maria Buti, Chair of the Policy and Public Health Committee at EASL | ||||||||
| Capital Suite 5 Level 3 |
Philippa Easterbrook, Medical Expert, WHO Global HIV, Hepatitis and STI Programme at the World Health Organization | ||||||||||
| TIME (BST) | THEME / TOPIC | TIME OF | SPEAKERS | ||||||||
| PRESENTATIONS | |||||||||||
| Friday June 24 | ILC 2022 Official Press Conference: Non Alcoholic Fatty Liver Disease (NAFLD) | Chair: Aleksander Krag, Vice-Secretary, EASL, Denmark | |||||||||
| 11:30-12:15 BST | |||||||||||
| The global burden of liver cancer (LC) and chronic liver diseases (CLD) is driven by non-alcoholic steatohepatitis (NASH) and alcohol liver disease (ALD) (GS008) | Friday 24 June 13:40 - 15:40 |
Zobair Younossi, Chairman, Department of Medicine, Inova Health System, Center for Liver Diseases, Betty and Guy Beatty Center for Integrated Research, IHS, Inova Health System, Medicine Service Line, United States | |||||||||
| Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial (OS124) | Saturday 25 June 17:30 - 19:00 |
Scott Harris, Chief Medical Officer, Altimmune, Inc., Medical, Gaithersburg, United States | |||||||||
| Biomarkers, imaging and safety in a well-compensated NASH cirrhotic cohort treated with resmetirom, a thyroid hormone receptor beta agonist, for 52 weeks (OS121) | Saturday 25 June 17:30 - 19:00 |
Stephen Harrison, Medical Director, Pinnacle Research, United States | |||||||||
| A non-calorie restricted low carbohydrate high fat diet improves nonalcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in type 2 diabetes: a six-month randomised controlled trial (GS012) | Friday 24 June 13:40 - 15:40 |
Camilla Dalby Hansen, PhD Student, Odense University Hospital, Gastroenterology and hepatology, Odense, Denmark, University of Southern Denmark, Clinical institute, Odense, Denmark | |||||||||
